



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 416 951 A1

⑫

EUROPEAN PATENT APPLICATION

⑲ Application number: 90309846.5

⑤① Int. Cl.⁵: **A61K 31/57, //(A61K31/57, 31:135)**

⑳ Date of filing: 07.09.90

③① Priority: 08.09.89 GB 8920392
20.10.89 GB 8923644

④③ Date of publication of application:
13.03.91 Bulletin 91/11

⑤④ Designated Contracting States:
AT DE DK ES GR LU NL SE

⑦① Applicant: **GLAXO GROUP LIMITED**
Clarges House 6-12 Clarges Street
London W1Y 8DH(GB)

⑦② Inventor: **Palmer, James Barry Douglas**
Glaxo Group Research Limited, Berkeley
Avenue
Greenford, Middlesex UB6 0HE(GB)

⑦④ Representative: **Holmes, Michael John et al**
Frank B. Dehn & Co. Imperial House 15-19
Kingsway
London WC2B 6UZ(GB)

⑤④ Medicaments.

⑤⑦ Pharmaceutical compositions comprising effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.

EP 0 416 951 A1

MEDICAMENTS

This invention relates to improvements in the treatment of asthma and other respiratory disorders. More particularly, it relates to the use of a bronchodilator drug in combination with a steroidal anti-inflammatory drug for the treatment of respiratory disorders such as asthma, and to pharmaceutical compositions containing the two active ingredients.

5 Asthma is a condition characterised by variable, reversible obstruction of the airways which is caused by a complex inflammatory process within the lungs. In most cases, this process is initiated and maintained by the inhalation of antigens by sensitive atopic individuals (extrinsic asthma). However, in some patients it is caused by other mechanisms which at present are poorly understood but do not involve an allergic process (intrinsic asthma). The disease has therefore two components, spasm of the bronchial (or
10 breathing) tubes and inflammation or swelling of the breathing tubes.

Salbutamol, the first highly selective β_2 -adrenoceptor stimulant has been used successfully and effectively by inhalation for the immediate relief of spasm in asthma. However, when given by inhalation, salbutamol has usually a four to six hour duration of action, which is too short either to control nocturnal asthma or for convenient maintenance of the disease in some patients.

15 Anti-inflammatory corticosteroids such as, for example, beclomethasone dipropionate have also been administered by inhalation in the treatment of asthma, although unlike salbutamol the therapeutic benefits resulting from reduced inflammation may not be immediately apparent.

It has been recognised that asthma may be treated by using both a bronchodilator for immediate relief and a prophylactic anti-inflammatory corticosteroid to treat the underlying inflammation. Such combination
20 therapy directed at the two main underlying events in the lung (i.e. relief of spasm in the breathing tubes and treatment of inflammation in the breathing tubes) using a combination of salbutamol and beclomethasone dipropionate has previously been proposed (Ventide, Glaxo Group trade mark), but suffers a number of disadvantages in view of the above-mentioned short duration of action exhibited by salbutamol. Thus the need for a 4-hourly dosing regimen may discourage effective patient compliance and also renders
25 the product less than satisfactory in the treatment of nocturnal asthma since the bronchodilator may not remain effective for the duration of the night, leading to impaired sleep for asthmatics troubled by nocturnal cough, breathlessness and wheeze.

The present invention is based on the concept of a novel combination therapy which has markedly greater efficiency and duration of bronchodilator action than previously known combinations and which
30 permits the establishment of a twice daily (*bis in diem* - b.i.d) dosing regimen with consequent substantial benefits in, for example, the treatment of asthma, particularly nocturnal asthma.

Thus we have found that if the β_2 -adrenoreceptor stimulant bronchodilator salmeterol and/or a physiologically acceptable salt thereof is combined with the anti-inflammatory corticosteroid fluticasone propionate in a form suitable for administration by inhalation, the resulting compositions may be administered
35 on a b.i.d. basis to provide highly effective treatment and/or prophylactic therapy for asthmatics. In particular such administration has been shown to lead to significant improvement in daytime lung function, requirement for additional symptomatic bronchodilator and almost complete abolition of nocturnal asthma while giving rise to minimal systemic side effects.

Salmeterol is one of a range of bronchodilators having extended duration of action which is described in
40 British Patent Specification No. 2140800, and is systematically named 4-hydroxy- α^1 -[[[6-(4-phenylbutoxy)-hexyl]amino]methyl]-1,3-benzenedimethanol. Fluticasone propionate is one of a range of topical anti-inflammatory corticosteroids with minimal liability to undesired systemic side effects which is described in British Patent Specification No. 2088877, and is systematically named S-fluoromethyl 6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-17 α -propionyloxy-3-oxoandrosta-1,4-diene-17 β -carbothioate. We have found these two
45 compounds to be particularly compatible and complementary in their activity and thus highly effective in the treatment of asthma and other respiratory disorders.

Thus according to one aspect of the invention there are provided pharmaceutical compositions comprising effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation
50 in the treatment of respiratory disorders.

The invention additionally relates to the use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate in the manufacture of pharmaceutical compositions as combined preparations for simultaneous, sequential or separate administration of salmeterol and fluticasone propionate by inhalation in the treatment of respiratory disorders.

According to a further feature of the invention there is provided a method of treating respiratory

disorders which comprises the simultaneous, sequential or separate administration by inhalation of effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate.

Suitable physiologically acceptable salts of salmeterol include acid addition salts derived from inorganic and organic acids, such as the hydrochloride, hydrobromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate, acetate, fumarate, succinate, lactate, glutarate, gluconate, tricarballic acid, hydroxynaphthalenecarboxylate e.g. 1-hydroxy- or 3-hydroxy-2-naphthalenecarboxylate, or oleate. Salmeterol is preferably used in the form of its 1-hydroxy-2-naphthalene carboxylate salt (hydroxynaphthoate).

For administration by inhalation, the compositions according to the invention are conveniently delivered by conventional means, e.g. in the form of a metered dose inhaler prepared in a conventional manner or in combination with a spacer device such as the Volumatic (Glaxo Group trade mark) device. In the case of a metered dose inhaler, a metering valve is provided to deliver a metered amount of the composition. Spray compositions may for example be formulated as aqueous solutions or suspensions and may be administered by a nebuliser. Aerosol spray formulations, for example in which the active ingredients are suspended, optionally together with one or more stabilisers, in a propellant, e.g. a halogenated hydrocarbon such as trichlorofluoromethane, dichlorodifluoromethane, 1,2-dichlorotetrafluoroethane, trichlorotrifluoroethane, monochloropentafluoroethane, chloroform or methylene chloride, may also be employed. The two drugs may be administered separately in similar ways.

Alternatively, for administration by inhalation or insufflation, the compositions according to the invention may take the form of a dry powder composition, for example a powder mix of the active ingredients and a suitable carrier such as lactose. The powder compositions may be presented in unit dosage form in, for example, capsules, cartridges or blister packs from which the powder may be administered with the aid of an inhaler such as the Rotahaler inhaler (Glaxo Group trade mark) or in the case of blister packs by means of the Diskhaler inhaler (Glaxo Group trade mark).

The ratio of salmeterol to fluticasone propionate in the compositions according to the invention is preferably within the range 4:1 to 1:20. The two drugs may be administered separately in the same ratio. Each metered dose or actuation of the inhaler will generally contain from 25 μ g to 100 μ g of salmeterol and from 25 μ g to 500 μ g of fluticasone propionate. As hereinbefore indicated, it is intended that the pharmaceutical compositions will be administered twice daily.

A suitable daily dose of salmeterol for inhalation is in the range 50 μ g to 200 μ g.

A suitable daily dose of fluticasone propionate for inhalation is in the range 50 μ g to 2000 μ g depending on the severity of the disease.

The precise dose employed will of course depend on the method of administration, the age, weight and condition of the patient and will be determined by the clinician depending on the severity and the type of asthma.

In order that the invention may be more fully understood, the following examples are given by way of illustration only.

EXAMPLE 1 - Metered Dose Inhaler

Active Ingredient	Target per Actuation	Per Inhaler % w/w
Salmeterol (as hydroxynaphthoate)	25.0 μ g	0.0448
Fluticasone propionate	25.0 μ g	0.0309
Stabiliser	5.0 μ g	0.0076
Trichlorofluoromethane	23.70 mg	27.8759
Dichlorodifluoromethane	61.25 mg	72.0588

EXAMPLE 2 - Metered Dose Inhaler		
Active Ingredient	Target per Actuation	Per Inhaler % w/w
Salmeterol (as hydroxynaphthoate)	25.0 µg	0.0448
Fluticasone propionate	50.0 µg	0.0618
Stabiliser	7.5 µg	0.0106
Trichlorofluoromethane	23.67 mg	27.8240
Dichlorodifluoromethane	61.25 mg	72.0588

EXAMPLE 3 - Metered Dose Inhaler		
Active Ingredient	Target per Actuation	Per Inhaler % w/w
Salmeterol (as hydroxynaphthoate)	25.0 µg	0.0448
Fluticasone propionate	250.0 µg	0.3088
Stabiliser	25.0 µg	0.0309
Trichlorofluoromethane	23.45 mg	27.5567
Dichlorodifluoromethane	61.25 mg	72.0588

EXAMPLE 4 - Metered Dose Inhaler		
Active Ingredient	Target per Actuation	Per Inhaler % w/w
Salmeterol (as hydroxynaphthoate)	25.0 µg	0.0448
Fluticasone propionate	125.0 µg	0.1544
Stabiliser	15.0 µg	0.0175
Trichlorofluoromethane	23.56 mg	27.7244
Dichlorodifluoromethane	61.25 mg	72.0588

EXAMPLE 5 - Metered Dose Inhaler		
Active Ingredient	Target per Actuation	Per Inhaler % w/w
Salmeterol (as hydroxynaphthoate)	100.0 µg	0.1791
Fluticasone propionate	250.0 µg	0.3088
Stabiliser	25.0 µg	0.0309
Trichlorofluoromethane	23.43mg	27.4224
Dichlorodifluoromethane	61.25 mg	72.0588

In Examples 1 to 5 micronised fluticasone propionate and micronised salmeterol (as the hydroxynaphthoate) are added in the proportions given above either dry or after predispersal in a small quantity of stabiliser (disodium dioctylsulphosuccinate, lecithin, oleic acid or sorbitan trioleate)/trichlorofluoromethane

solution to a suspension vessel containing the main bulk of the trichlorofluoromethane solution. The resulting suspension is further dispersed by an appropriate mixing system using, for example, a high shear blender, ultrasonics or a microfluidiser until an ultrafine dispersion is created. The suspension is then continuously recirculated to suitable filling equipment designed for cold fill or pressure filling of dichlorodifluoromethane. Alternatively, the suspension may be prepared in a suitable chilled solution of stabiliser, in trichlorofluoromethane/dichlorodifluoromethane.

EXAMPLE 6 - Metered Dose Dry Powder Formulation		
Active Ingredient		μ g/cartridge or blister
Salmeterol (as hydroxynaphthoate)		36.3
Fluticasone propionate		50.00
Lactose Ph.Eur.	to	12.5 mg or
	to	25.0mg

EXAMPLE 7 - Metered Dose Dry Powder Formulation		
Active Ingredient		μ g/cartridge or blister
Salmeterol (as hydroxynaphthoate)		72.5
Fluticasone propionate		50.00
Lactose Ph.Eur.	to	12.5 mg or
	to	25.0 mg

EXAMPLE 8 - Metered Dose Dry Powder Formulation		
Active Ingredient		μ g/cartridge or blister
Salmeterol (as hydroxynaphthoate)		72.5
Fluticasone propionate		100.00
Lactose Ph.Eur.	to	12.5 mg or
	to	25.0 mg

EXAMPLE 9 - Metered Dose Dry Powder Formulation		
Active Ingredient		$\mu\text{g}/\text{cartridge or blister}$
Salmeterol (as hydroxynaphthoate)		72.5
Fluticasone propionate		250
Lactose Ph.Eur.	to	12.5 mg or
	to	25.0 mg

EXAMPLE 10 - Metered Dose Dry Powder Formulation		
Active Ingredient		$\mu\text{g}/\text{cartridge or blister}$
Salmeterol (as hydroxynaphthoate)		72.5
Fluticasone propionate		500.0
Lactose Ph. Eur.	to	12.5 mg or
	to	25.0 mg

EXAMPLE 11 - Metered Dose Dry Powder Formulation		
Active Ingredient		$\mu\text{g}/\text{cartridge or blister}$
Salmeterol (as hydroxynaphthoate)		145.0
Fluticasone propionate		250.0
Lactose Ph. Eur.	to	12.5 mg or
	to	25.0 mg

In Examples 6 to 11 the active ingredients are micronised and bulk blended with the lactose in the proportions given above. The blend is filled into hard gelatin capsules or cartridges or in specifically constructed double foil blister packs (Rotadisks blister packs, Glaxo Group trade mark) to be administered by an inhaler such as the Rotahaler inhaler (Glaxo Group trade mark) or in the case of the blister packs with the Diskhaler inhaler (Glaxo Group trade mark).

Claims

1. Pharmaceutical compositions comprising effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.
2. Compositions as claimed in claim 1 wherein salmeterol is present as its 1-hydroxy-2-naphthoate salt.
3. Compositions as claimed in claim 1 or claim 2 presented as a metered spray composition or a dry powder composition.
4. Compositions as claimed in any of claims 1 to 3 in dosage unit form containing 25-100 μg of salmeterol (optionally in the form of a physiologically acceptable salt thereof) and 25-500 μg of fluticasone propionate

per dosage unit.

5. The use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate in the manufacture of pharmaceutical compositions as combined preparations for simultaneous, sequential or separate administration of salmeterol and fluticasone propionate by inhalation in the treatment of respiratory disorders.

6. The use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate according to claim 5 in the manufacture of pharmaceutical compositions for administration on a twice daily basis.

10 Claims for the following Contracting States: GR, ES

1. The use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate in the manufacture of pharmaceutical compositions as combined preparations for simultaneous, sequential or separate administration of salmeterol and fluticasone propionate by inhalation in the treatment of respiratory disorders.

2. The use according to claim 1 wherein salmeterol is present as its 1-hydroxy-2-naphthoate salt.

3. The use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate according to claim 1 or claim 2 in the manufacture of compositions as claimed in claim 1 or claim 2 presented as a metered spray composition or a dry powder composition.

4. The use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate according to any of claims 1 to 3 in the manufacture of compositions as claimed in any of claims 1 to 3 in dosage unit form containing 25-100µg of salmeterol (optionally in the form of a physiologically acceptable salt thereof) and 25-500µg of fluticasone propionate per dosage unit.

5. The use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate according to any of claims 1 to 4 in the manufacture of pharmaceutical compositions for administration on a twice daily basis.



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 30 9846

DOCUMENTS CONSIDERED TO BE RELEVANT					
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)		
D,A	GB-A-2 140 800 (GLAXO GROUP LTD U.K.) * Page 4, lines 21-26 * - - -	1-6	A 61 K 31/57 // (A 61 K 31/57 A 61 K 31:135)		
A	UNLISTED DRUGS, vol. 33, no. 6, June 1981, page 101c, Chatnam, New Jersey, US; "Ventolin compositum" - - -	1-6			
A	GB-A-2 107 715 (GLAXO GROUP LTD U.K.) * Page 5, line 14; claim 11 * - - -	1-6			
A	EP-A-0 223 671 (CENTRE INTERNATIONAL DE RECHER- CHES DERMATOLOGIQUES C.I.R.D.) - - - - -	1-6			
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)		
			A 61 K		
The present search report has been drawn up for all claims					
Place of search The Hague		Date of completion of search 29 November 90	Examiner BRINKMANN C.		
<table border="0"><tr><td>CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention</td><td>E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document</td></tr></table>				CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention	E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention	E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document				